Pharmaceuticals, Biotechnology and Life Sciences
– Data from three cohorts of phase 1b COSMIC-021 trial to be presented during the 2020 American Society of Clinical…
– Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung…
Opdivo plus Yervoy continues to demonstrate sustained improvement in overall survival over chemotherapy, with 33% of patients still alive after…
Opdivo plus Yervoy given concomitantly with two cycles of chemotherapy demonstrated prolonged overall survival at an interim analysis, with sustained…
First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0%…
— Nine Abstracts, Including Three Oral Presentations, Highlight Leadership in Hematologic Malignancies and Early Progress in Solid Tumors — —…
Schrödinger has reported a total revenue of $26.2 million and strong growth of 26% year-over-year, with record software revenue of $23.8 million, up 28% year-over-year, while it also raised $209.6 million in net proceeds through initial public offering.
Novocure’s Optune has became the first innovative treatment for glioblastoma approved in China in over 15 years, the company said in a Wednesday press release, after it’s global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) said Wednesday in a press release that it has withdrawn the New Drug Applications…
QurAlis has raised $42 million in Series A funding to develop new therapies for amyotrophic lateral sclerosis (ALS).